IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF WEST VIRGINIA

NOVO NORDISK INC. and NOVO NORDISK A/S,

Plaintiffs,

v.

C.A. No. 1:23-cv-13

VIATRIS INC. and MYLAN PHARMACEUTICALS INC.,

Defendant.

JOINT MOTION FOR EXTENSION

Plaintiffs Novo Nordisk Inc. and Novo Nordisk A/S, and Defendants Viatris Inc. and Mylan Pharmaceuticals Inc., by their undersigned counsel, hereby move the Court for an extension of the deadlines for the Initial Disclosures that are currently due to be exchanged by June 5, 2023, under the Court's First Order and Notice Regarding Discovery and Scheduling Conference dated April 3, 2023 (Dkt. No. 27), the Initial Planning Meeting that is currently due May 31, 2023, and the Joint Report of Initial Planning Meeting that is currently due June 14, 2023, under the Court's Order Extending Deadlines dated May 18, 2023 (Dkt. No. 32).

The parties respectfully and jointly request that the Court extend the deadline for the Initial Disclosures through and until June 19, 2023, the Initial Planning Meeting through and until June 14, 2023, and the deadline to submit the Joint Report of Initial Planning Meeting through and until June 28, 2023. The parties represent that the additional time will permit counsel to further confer with their clients and with each other, allowing for a Joint Report with as few areas of disagreement as possible.

Dated: June 1, 2023

Respectfully submitted,

SCHRADER COMPANION DUFF & LAW, PLLC

/s/ James F. Companion James F. Companion (#790) Sandra K. Law (#6071) 401 Main Street Wheeling, WV 26003 (304) 233-3390 jfc@schraderlaw.com skl@schraderlaw.com

DOCKE

Δ

Attorneys for Plaintiffs, Novo Nordisk Inc and Novo Nordisk A/S PERKINS COIE LLP

/s/ Brandon M. White Brandon M. White (WV Bar No. 14021) BMWhite@perkinscoie.com PERKINS COIE LLP 700 13th Street, NW, Suite 800 Washington, DC 20005 (202) 654-6200 bmwhite@perkinscoie.com

Attorney for Defendants Viatris Inc. and Mylan Pharmaceuticals Inc.